Multicenter, Prospective Adaptive Response Placebo-controlled Double-blind Study Comparing Effects of Rosuvastatin Versus Placebo
Phase of Trial: Phase 0
Latest Information Update: 17 Oct 2017
Price : $35 *
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Atherosclerosis; HIV-1 infections
- Focus Biomarker; Pharmacodynamics
- Acronyms SPARC
- 10 May 2016 Status changed from active, no longer recruiting to completed.
- 26 May 2015 Planned End Date changed from 1 May 2015 to 1 May 2016, according to ClinicalTrials.gov record
- 26 May 2015 Planned primary completion date changed from 1 May 2015 to 1 Nov 2015 according to ClinicalTrials.gov record.